A phase 2 trial investigating an 8 mg dose of aflibercept revealed no new safety signals compared with aflibercept 2 mg in patients with wet age-related macular degeneration, according to a press release from Regeneron Pharmaceuticals.
A higher proportion of patients who received the 8 mg dose of aflibercept in the proof-of-concept trial had no retinal fluid at week 16 compared with patients treated with currently approved Eylea (aflibercept 2 mg), 43.4% vs. 26.4%. The difference was not statistically significant.
In the first 16 weeks of the trial, adverse events (Read more...)